Aortic Graft Infections after Emergency and Non-Emergency Reconstruction: Incidence, Treatment, and Long-Term Outcome

Pettersson, Jennifer; Daryapeyma, Alireza; Gillgren, Peter; Hultgren, Rebecka

doi:10.1089/sur.2016.225

Cited by 10 publications

(3 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One patient developed an aortic stent graft infection, however of unknown origin. The incidence of aortic stent graft infections in the present study was lower than the incidence of 1.4% previously reported in a retrospective study [ 17 ]. The low incidence of aortic stent graft infections could be due to a too short follow-up time since the reported median time to aortic stent graft infection in that study was 3.2 years.…”

Section: Discussioncontrasting

confidence: 85%

“…The low incidence of aortic stent graft infections could be due to a too short follow-up time since the reported median time to aortic stent graft infection in that study was 3.2 years. [ 17 ] All the SSIs in the present study were diagnosed within 30 days postoperatively, indicating no need for a prolonged wound surveillance time of up to 90 days.…”

Section: Discussionmentioning

confidence: 68%

See 1 more Smart Citation

Negative Pressure Wound Therapy for the Prevention of Surgical Site Infections Using Fascia Closure After EVAR—A Randomized Trial

et al. 2022

View full text Add to dashboard Cite

Background Surgical site infections (SSI) in the groin after vascular surgery are common. The aim of the study was to evaluate the effect of negative pressure wound therapy (NPWT) on SSI incidence when applied on closed inguinal incisions after endovascular aneurysm repair (EVAR). Methods A multicenter randomized controlled trial (RCT). Between November 2013 and December 2020, 377 incisions (336 bilateral and 41 unilateral) from elective EVAR procedures with the primary intent of fascia closure were randomized and included, receiving either NPWT or a standard dressing. In bilateral incisions, each incision randomly received the opposite dressing of the other side, thereby becoming each other’s control. The primary endpoint was SSI incidence at 90 days postoperatively, analyzed on an intention-to-treat basis. Uni and bilaterally operated incisions were analyzed separately, and their respective p-values combined using Fisher’s method for combining P-values. Study protocol (NCT01913132). Results The SSI incidence at 90 days postoperatively in bilateral incisions was 1.8% (n = 3/168) in the NPWT and 4.8% (n = 8/168) in the standard dressing group, and in unilateral incisions 13.3% (n = 2/15) and 11.5% (n = 3/26), respectively (combined p = 0.49). In all SSIs, bacteria were isolated from incisional wound cultures. No additional SSIs were diagnosed between 90 days and 1 year follow-up. Conclusions No evidence of difference in SSI incidence was seen in these low-risk inguinal incisions when comparing NPWT with standard dressings after EVAR with the primary intent of fascia closure. Clinical Trials: NCT01913132.

show abstract

Section: Discussioncontrasting

confidence: 85%

Section: Discussionmentioning

confidence: 68%

Negative Pressure Wound Therapy for the Prevention of Surgical Site Infections Using Fascia Closure After EVAR—A Randomized Trial

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Despite the improvements in perioperative management, surgical techniques, and vascular grafts, there are still quite a number of infected arterial grafts in the aorto-iliac position (1, 2) facing vascular surgeons with difficult decisions. One of them is which replacement material might be the best in terms of reinfection rate, durability, accessibility, and surgical trauma (3).…”

Section: Introductionmentioning

confidence: 99%

Biosynthetic vascular graft: a valuable alternative to traditional replacement materials for treatment of prosthetic aortic graft infection?

et al. 2018

View full text Add to dashboard Cite

Background and Aims: To report the experience of a tertiary vascular surgery center using Omniflow II® biosynthetic vascular grafts for treatment of prosthetic aortic graft infection. Materials and methods: Retrospective analysis of all patients with prosthetic graft infections who underwent in situ aortic reconstruction using Omniflow II® grafts or other conduits between March 2015 and May 2017. Early and late mortality, perioperative complications, and reinfection rate were analyzed. Results: Sixteen patients (14 males, median age 68.5, range 57–89) with prosthetic aortic graft infection were treated at our center. Eight patients received an Omniflow II® biosynthetic graft, two patients silver-triclosan coated grafts, three patients bovine pericardial tube grafts, and three patients composite bovine pericardial tube grafts with Omniflow II® graft extensions. Perioperative complications occurred in seven patients (43.8%). Early mortality rate was 18.7% (n = 3). In addition, four patients died during follow-up after a median of 11 months (range 0–34 months). We did not observe any reinfections. Bypass grafts were patent in all patients. No major limb amputations were performed during follow-up. Conclusion: Treatment of prosthetic aortic graft infection with Omniflow II® vascular grafts is feasible. Graft material seems to have an excellent resistance to infection and might be a valuable alternative to traditional replacement materials. Especially long-term durability has to be continuously monitored and documented.

show abstract

A 57-Year-Old Man With Subacute Progressive Hemoptysis and Fevers

Sumarsono

Brown

Atkin

et al. 2018

Chest

View full text Add to dashboard Cite

Aortic Graft Infections after Emergency and Non-Emergency Reconstruction: Incidence, Treatment, and Long-Term Outcome

Cited by 10 publications

References 22 publications

Negative Pressure Wound Therapy for the Prevention of Surgical Site Infections Using Fascia Closure After EVAR—A Randomized Trial

Negative Pressure Wound Therapy for the Prevention of Surgical Site Infections Using Fascia Closure After EVAR—A Randomized Trial

Biosynthetic vascular graft: a valuable alternative to traditional replacement materials for treatment of prosthetic aortic graft infection?

A 57-Year-Old Man With Subacute Progressive Hemoptysis and Fevers

Contact Info

Product

Resources

About